BioPharma
Beyond's analysis on BioPharma
- — Zenas BioPharma schedules investor event to showcase Obexelimab for IgG4-related disease development
- — Quantum BioPharma completes debt settlement, strengthening its balance sheet
Recent news mentioning BioPharma
- — GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
- — Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
- — Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
- — GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
- — Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
- — Crescent Biopharma Announces Grants of Inducement Awards
- — Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
- — Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
- — Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
- — Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff
- — Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
- — CelluPro erhält EXCiPACT™-Zertifizierung für die Herstellung von Zellkulturmedien in GMP-Qualität und stärkt damit seine globalen Lieferkapazitäten im Bereich der biopharmazeutischen Produktion